Marleen Hamoen

Marleen Hamoen

Auto-generated profile, based on publicly available information

Marleen Hamoen

Department of Public Health, University Medical Center Rotterdam, Wytemaweg 80, 3015CN Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Nienke van DokkumNienke van Dokkum
Nienke van Dokkum
SRSijmen Reijneveld
Sijmen Reijneveld
JBJudith Th. B. W. de Best
Judith Th. B. W. de Best
MHMarleen Hamoen
Marleen Hamoen
SWSanne C. M. Te Wierike
Sanne C. M. Te Wierike
MKMarlou L.A. De Kroon
Marlou L.A. De Kroon
The detection of motor developmental problems, especially developmental coordination disorder, at age 5–6 contributes to early interventions. Here, we summarize evidence on (1) criterion validity of screening instruments for motor developmental problems at age 5–6, and (2) their applicability. We systematically searched seven databases for studies assessing criterion validity of these screening instruments using the M-ABC as reference standard. We applied COSMIN criteria for systematic reviews of screening instruments to describe the correlation between the tests and the M-ABC. We extracted information on correlation coefficients or area under the receiver operating curve, sensitivity and specificity, and applicability in practice. We included eleven studies, assessing eight instruments: three performance-based tests (MAND, MOT 4–6, BFMT) and five questionnaires (DCD-Q, PQ, ASQ-3, MOQ-T-FI, M-ABC-2-C). The quality of seven studies was fair, one was good, and three were excellent. Seven studies reported low correlation coefficients or AUC (<0.70), four did not report these. Sensitivities ranged from 21–87% and specificities from 50–96%, with the MOT4–6 having the highest sensitivity and specificity. The DCD-Q, PQ, ASQ-3, MOQ-T-FI, and M-ABC-2-C scored highest on applicability. In conclusion, none of the instruments were sufficiently valid for motor screening at age 5–6. More research is needed on screening instruments of motor delay at age 5–6.

1 March 2020 in Preventive Medicine
Verified
Journal Article
Closed access
MHMarleen Hamoen
Marleen Hamoen
MWMarieke Welten
Marieke Welten
DNDaan Nieboer
Daan Nieboer
GBGUANNAN BAI
GUANNAN BAI
MHMartijn W. Heymans
Martijn W. Heymans
MKMarlou L.A. De Kroon
Marlou L.A. De Kroon

21 November 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
MHMarleen Hamoen
Marleen Hamoen
YVYvonne Vergouwe
Yvonne Vergouwe
AWAlet H Wijga
Alet H Wijga
MHMartijn W Heymans
Martijn W Heymans
VJVincent W V Jaddoe
Vincent W V Jaddoe
MKMarlou L A de Kroon
Marlou L A de Kroon
Objectives To develop a dynamic prediction model for high blood pressure at the age of 9–10 years that could be applied at any age between birth and the age of 6 years in community-based child healthcare. Design, setting and participants Data were used from 5359 children in a population-based prospective cohort study in Rotterdam, the Netherlands. Outcome measure High blood pressure was defined as systolic and/or diastolic blood pressure ≥95th percentile for gender, age and height. Using multivariable pooled logistic regression, the predictive value of characteristics at birth, and of longitudinal information on the body mass index (BMI) of the child until the age of 6 years, was assessed. Internal validation was performed using bootstrapping. Results 227 children (4.2%) had high blood pressure at the age of 9–10 years. Final predictors were maternal hypertensive disease during pregnancy, maternal educational level, maternal prepregnancy BMI, child ethnicity, birth weight SD score (SDS) and the most recent BMI SDS. After internal validation, the area under the receiver operating characteristic curve ranged from 0.65 (prediction at age 3 years) to 0.73 (prediction at age 5–6 years). Conclusions This prediction model may help to monitor the risk of developing high blood pressure in childhood which may allow for early targeted primordial prevention of cardiovascular disease.

1 May 2019 in Journal Of Hypertension
Verified
Journal Article
Open access
MHMarleen Hamoen
Marleen Hamoen
MKMarlou L.A. de Kroon
Marlou L.A. de Kroon
MWMarieke Welten
Marieke Welten
HRHein Raat
Hein Raat
JTJos W.R. Twisk
Jos W.R. Twisk
YVYvonne Vergouwe
Yvonne Vergouwe
Background: Hypertension, even during childhood, increases the risk of developing atherosclerosis and cardiovascular disease. Therefore, starting prevention of hypertension early in the life course could be beneficial. Prediction models might be useful for identifying children at increased risk of developing hypertension, which may enable targeted primordial prevention of cardiovascular disease. Objective: To provide an overview of childhood prediction models for future hypertension. Methods: Embase and Medline were systematically searched. Studies were included that were performed in the general population, and that reported on development or validation of a multivariable model for children to predict future high blood pressure, prehypertension or hypertension. Data were extracted using the CHARMS checklist for prediction modelling studies. Results: Out of 12 780 reviewed records, six studies were included in which 18 models were presented. Five studies predicted adulthood hypertension, and one predicted adolescent prehypertension/hypertension. BMI and current blood pressure were most commonly included as predictors in the final models. Considerable heterogeneity existed in timing of prediction (from early childhood to late adolescence) and outcome measurement. Important methodological information was often missing, and in four studies information to apply the model in new individuals was insufficient. Reported area under the ROC curves ranged from 0.51 to 0.74. As none of the models were validated, generalizability could not be confirmed. Conclusion: Several childhood prediction models for future hypertension were identified, but their value for practice remains unclear because of suboptimal methods, limited information on performance, or the lack of external validation. Further validation studies are indicated.

20 October 2017 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
MHM Hamoen
M Hamoen
Summary